In the postgenomic era, the functional analysis of the proteins encoded in the genomes is the ratelimiting step in understanding cellular processes. Most approaches in use today do not target the protein of interest directly, but prevent its synthesis, either by total gene knock-out (e.g. by homologous recombination), by antisense technologies or by RNA interference (RNAi; (1, 2) . While these technologies have generated remarkable insights into some intracellular protein functions, they suffer from a number of limitations: Total gene knockouts are often difficult to achieve and might even be lethal to the studied organism. Furthermore, the effects can be compromised by compensating changes in the regulation of other genes. The effect of antisense technologies is often not very strong. In a number of cases, even an 80% reduction of mRNA has no effect on the phenotype caused by the protein (3) . Furthermore, the interpretation of results obtained from RNAi can be complicated by the up-regulation of other genes, limitation in specificity, and induction of the interferon response (Jackson et al., Sledz et al., 2003) . Finally, all methods that prevent the synthesis of the entire protein only allow the description of a loss-of-function phenotype. The use of molecules acting at the protein level is a complementary approach. This approach has the additional advantage that single functions, domains or posttranslational modifications of a protein may be targeted, without removing the whole protein. Inhibitors of proteins can also be used in subsequent studies of the target protein in vitro, and might then even be used as first lead compounds in the drug discovery process or at least simulate the effect of a future small molecule drug. Both constrained peptides (4-7) and single-chain antibody fragments (scFv (8) ) have been applied for in vivo protein inhibition. In most cases, it is rather difficult to obtain highaffinity peptides to a target protein due to their high flexibility and the resulting loss of peptide chain entropy upon binding, limiting the free energy of binding, and thus the generation of high-affinity antibody fragments to a given target has been pursued more often (Hoogenboom and Chames, 2000) . However, the drawback of antibodies is that their functionality is compromised in the reducing environment inside the cell, as the stabilizing intramolecular disulfide bonds are not formed (Biocca et al., 1995) . While a number of antibody frameworks have been reported that are stable in the reducing environment (Wörn and Plückthun, 1998; Cattaneo and Biocca, 1999; Auf der Maur et al., 2002; Lobato and Rabbitts, 2003) , the stability in the reducing state still does not reach those of other proteins. The solution to this problem is to use alternative binding proteins without disulfide bonds. Such alternative scaffolds have been developed (9) (10) (11) , but only one intracellular selection for binding molecules with the yeast two-hybrid system has been published (12) ; no intracellular inhibitors have been reported up to date. We previously reported the generation of designed ankyrin repeat (AR) proteins as highaffinity binders with a great potential for intracellular applications (13, 14) . Next to antibodies, repeat proteins are the most abundant class of binding molecules found in nature (15) (16) (17) . Unlike antibodies, AR proteins do not contain disulfide bonds and are found in all cellular compartments, mediating protein-protein interactions with affinities in the nanomolar to picomolar range. They often act as intracellular enzyme modulators, for example, as inhibitors of kinases (18) . AR proteins are built of consecutive homologous repeats, which assemble to form elongated domains with a continuous hydrophobic core. The number of repeats found in natural AR proteins varies from 2 to over 30 (19, 20) . We used this modular architecture to generated designed AR protein libraries. By structure and sequence consensus analyses, we engineered an AR module of 33 amino acids with fixed framework residues and randomized potential interaction residues (21) . This module was used as building block to create combinatorial libraries of designed AR proteins of different repeat numbers (Fig. 1) . Members of these libraries are very well expressed, monomeric in solution, highly soluble and stable (21) . By X-ray crystallography, the expected AR domain fold could be verified (22) . Specific binders to maltose binding protein (MBP) of Escherichia coli and two human mitogenactivated protein kinases (JNK2 and p38) have been selected with dissociation constants in the low nanomolar range (13) .
Here, we report the first tailor-made enzyme inhibitors based on designed AR proteins. Using a combination of in vitro selection and in vivo screening, we isolated designed AR proteins that specifically bind and inhibit aminoglycoside phosphotransferase type (3')-IIIa (APH). APH is a bacterial kinase conferring resistance to aminoglycoside antibiotics (23) and can serve as a model system, as it shows structural homology to eukaryotic protein kinases (EPKs). We show that the selected AR proteins inhibit APH both in vitro and in vivo. Based on these results, the use of designed AR proteins as specific kinase inhibitors and as general intracellularly active tools is discussed. We describe elsewhere (24) the crystal structure of one selected APH inhibiting AR protein in complex with APH and report the details of the inhibition mechanism of this particular inhibitor.
Materials and methods
Molecular Biology -Unless stated otherwise, all experiments were performed according to protocols of (25). Enzymes and buffers were from New England Biolabs (Beverly, MA, USA) or Fermentas (Vilnius, Lithuania). Oligonucleotides were from Microsynth (Balgach, Switzerland). Antigen cloning and production -The APH gene was amplified from the plasmid pETSACG1 (a kind gift from Prof. G. Wright (26, 27) ; with the oligonucleotides APHf (5'-GCCGGCCATGGGTACCGCTAAAATGAGA ATA-3') and APHr (5'-GCATAAGCTTTCATTAAAACAATTCATCC A-3'). The PCR product was purified (QIAquick; QIAgen, Hilden, Germany), cut with NcoI/HindIII and ligated into pAT223 (GenBank accession number AY327138), which is a pQE30 (QIAgen, Hilden, Germany) derivative, yielding pAT223_APH. The expression from this vector yields a fusion protein with an Nterminal avi-tag for in vivo biotinylation, pD as fusion protein, a His 6 -tag for IMAC purification and APH as target molecule (avi-pD-His 6 -APH). Protein production and purification -The biotinylated proteins avi-pD-His 6 -APH and avipD-His 6 were produced according to protocols from Avidity (Denver, CO, USA) and QIAgen by in vivo biotinylation in E. coli XL1-Blue (Stratagene, La Jolla, CA, USA), which was cotransformed with pBirAcm (Avidity) and pAT223 or pAT223_APH, respectively. Successful biotinylation of the IMAC purified proteins was confirmed by detection of the biotin-tag on immobilized proteins using ELISA and blotting procedures with a streptavidinalkaline phosphatase conjugate (Roche; Basel, Switzerland) as detection reagent. Non-biotinylated wild-type APH used for the in vitro kinetic assays was expressed from pETSACG1 in BL21 cells (Stratagene) and purified over a Q-Sepharose column (Amersham Pharmacia, Dübendorf, Switzerland), followed by gel-filtration (Superdex 75; Pharmacia) as described (28) with some modifications (for details, see Supplemental Data). The correct size of APH was confirmed by SDS-PAGE, mass spectrometry and static light scattering. For protein production of the AR proteins, the corresponding genes were isolated from pQIA (see below) and inserted into pQE30, to avoid co-purification of APH at a later stage. The proteins were expressed and purified by IMAC as described (22) . In vitro selection with ribosome display -The PCR amplified N2C and N3C AR protein libraries (13) were transcribed and selections were performed by ribosome display as described (29) on avi-pD-His 6 -APH immobilized over its biotinylated avi-tag (for details, see Supplemental Data). The number of total RT-PCR cycles after each selection round was reduced from round to round from 40 to 35 to 30, adjusting to the yield due to enrichment of binders. In vivo selection by replica plating -For the in vivo selection, the vector pQIA was constructed with β-lactamase and APH dicistronically arranged under the control of the β-lactamase promoter, as well as an expression cassette for AR proteins under the control of an IPTGinducible T5-promoter (Fig. 3A) . For details, see Supplemental Data. The pools of binders selected by ribosome display were cloned into pQIA using the restriction enzymes BamHI and HindIII, transformed into E. coli (XL1-Blue) and plated on LB agar plates, containing 1% glucose, 50 µg/ml ampicillin and 100 µM IPTG, and incubated overnight at 37°C. The colonies were replica-plated on selective plates containing 1% glucose, 50 µg/ml ampicillin, 500 µg/ml kanamycin A and 100 µM IPTG using Accutran replica plater devices (Schleicher & Schuell; Keene, NH, USA), incubated for 2 h at 4°C and finally incubated overnight at 37°C. Colonies whose replica failed to grow on the selective plates were taken up in LB and replica spotted again on selective plates to make sure no false positives were selected due to incomplete replica plating. By this procedure 198 kanamycin A sensitive colonies were identified. All of these clones were ranked for their kanamycin A sensitivity by spotting them on selection plates with kanamycin A at concentrations of 50, 100, 250 and 500 µg/ml. The plasmids of the most potent inhibitors were isolated and sequenced using standard DNA sequencing. Determining the minimal inhibitory constants (MICs) -Overnight cultures of E. coli (XL1-Blue) harboring pQIA, encoding an AR protein, were grown in LB with 1% glucose and 50 µg/ml ampicillin (LB-Glc-ampicillin) at 37°C overnight. The cultures were diluted 1/30 into 5 ml of the same medium and shaken at 37°C until an OD 600 of 0.3 was reached. The cultures were then diluted 1/1000 (~2.5 x 10 5 colony forming units/ml) into deep well plates (Abgene, Epsom, Surray, UK) containing 1 ml of the different selection media: LB-Glc-ampicillin-IPTG (100 µM)-kanamycin A (0, 1, 5, 10, 25, 50, 100, 150, 250, 500 or 1000 µg/ml) and as a control LB-Glc-ampicillin with 1000 µg/ml kanamycin A (without IPTG) and shaken at 37°C for 24 h. Growth was monitored by following the OD 600 ELISA -To determine the specificity of the interaction between the selected AR proteins and APH, ELISA experiments were performed as described (13) . Biotinylated proteins (avi-pDHis 6 -APH, avi-pD-His 6 , avi-pD-His 6 -JNK2, avipD-His 6 -p38, final concentration 100 nM) were immobilized in neutravidin-coated ELISA plates blocked with BSA. AR proteins (200 nM) were added for 30 min and, subsequently, the plates were washed five times. A first antibody against the RGS-His 6 -tag of the AR protein (QIAgen; detects only the RGS-His 6 -tag of the AR protein, but not the His 6 -tag of the antigen), followed by a secondary antibody/alkaline phosphatase conjugate (PIERCE) were used for detection. Surface plasmon resonance -SPR was measured using a BIAcore3000 instrument (BIAcore; Uppsala, Sweden) at 20°C. The running buffer was 20 mM HEPES pH 7.4, 150 mM NaCl, 10 mM MgCl 2 , 1 mM DTT, 0.005% Tween-20. A SA chip (BIAcore) was used with 600 RU biotinylated avi-pD-His 6 -APH immobilized. The interactions were measured at a flow of 60 µl/min with 5 minutes buffer flow, two minutes injection of APH-binding AR protein in varying concentrations (1 nM to 200 nM) and an off-rate measurement of 40 minutes with buffer flow. The signal of an uncoated reference cell was subtracted from the measurements. The kinetic data of the interaction were evaluated using BIAevaluation 3.0 (BIAcore), and global fits were used to determine K D . The affinities of the clone AR_3 variants were confirmed by competition BIAcore (Supplemental Data).
In vitro inhibition studies -APH activity assays were performed essentially as described (28) with small modifications. Briefly, the kinase buffer we used (50 mM HEPES pH 7.5, 160 mM NaCl, 40 mM KCl, 10 mM MgCl 2 , 0.025% BSA, 5 units of PK/LDH, 2.5 mM phosphoenolpyruvate, 0.12 mg/ml NADH, 1 mM ATP) contains HEPES instead of Tris, additionally 160 mM NaCl, 0.025% BSA and a lower concentration of NADH (0.12 instead of 0.5 mg/ml). APH was present at a concentration of 200 nM, while the AR proteins were present at 10 µM for the kanamycin A studies. This mixture (990 µl) was preincubated for 15 min and the assay was initiated by addition of 10 µl of kanamycin A solution (Sigma, K4000; 10 µM final concentration). Both the preincubation and the assay were carried out at 37°C. For the studies with amikacin, both the preincubation and the assay were carried out at 20°C in the presence of 2 µM AR proteins and the reaction was started with 10 µl of amikacin solution (Sigma, A1774; 740 µM final concentration). The initial rates were normalized for background activity by subtracting the activity monitored in the absence of substrate.
Results
To identify APH inhibitors we applied a twostep approach of in vitro selection and in vivo screening. First, we used ribosome display to select APH binders from highly diverse combinatorial AR protein libraries. The resulting pools of binders were subsequently screened for inhibitors by replica plating. As APH mediates bacterial resistance to aminoglycoside antibiotics, inhibitors of the enzyme give rise to a kanamycin sensitive phenotype.
Selection for APH binders with ribosome display
The AR protein libraries used here (13) were termed N2C and N3C. The digit describes the number of designed and randomized AR modules between the N-and C-terminal capping repeats in the library members ( Fig. 1 ). Three rounds of ribosome-display selection were carried out for both the N2C and the N3C AR protein libraries in parallel. Selections were performed using purified target protein. For this purpose, APH was expressed as a fusion to bacteriophage lambda protein D (pD; (30)) with an N-terminal avi-tag for in vivo biotinylation (31) and a His 6 -tag in the linker for immobilized metal-ion affinity chromatography (IMAC) purification (avi-pD-His 6 -APH). This target protein and the same construct without the kinase (avi-pD-His 6 ) were expressed in soluble and biotinylated form in E. coli by using the expression plasmids pAT223_APH and pAT223, respectively. For ribosome-display selections, purified biotinylated APH was immobilized on neutravidin-coated wells blocked with bovine serum albumin (BSA). To eliminate BSA-, neutravidin-and avi-pD-His 6 -binding library members, a pre-panning step on correspondingly immobilized avi-pD-His 6 was applied, where neutravidin and BSA were also present. In the actual panning step, binders to APH were thus selected. The relative amounts of ribosomal complexes binding to the target protein can be estimated by monitoring the yield from reverse transcription PCR (RT-PCR) on agarose gels. We observed a significant increase of RT-PCR yield when comparing the results from the first and the second selection round (Fig. 2) . To our knowledge, such pronounced enrichment after only one round of ribosome-display selection has not been reported for any kind of naïve library (scFv, cDNA or random sequence). This might indicate that AR protein libraries and ribosome display are a very favorable combination. In the third selection round, the selected pools of binders were analyzed for their specificity, comparing the RT-PCR yields after selection against APH or the unrelated MBP (Fig. 2) . High specificity to APH could be monitored by comparing the agarose gel band intensities of these RT-PCR products (Fig. 2) . In summary, we observed a rapid enrichment of binders and generated pools of specific binders in only three rounds of ribosome-display selection.
Screening for APH inhibitors by replica plating
The pools of specific binders were subjected to an in vivo screen, based on replica plating, to identify those APH-binding AR proteins that are also inhibitors. For this purpose, the selected pools of binders were cloned into the selection vector pQIA (Fig. 3A) . This vector carries an expression cassette for the selected APH binders under the control of an IPTG-inducible T5 promoter. pQIA also carries β-lactamase and APH as dicistronic genes under the control of the constitutively active β-lactamase promoter. Hence, this vector confers antibiotic resistance to ampicillin and kanamycin, of which the kanamycin resistance can be reverted, if an APH-inhibiting AR protein is expressed upon IPTG induction (Fig. 3A) . As a control, we tested E. coli transformed with a pQIA variant harboring the unselected AR protein E3_5 (22) in the expression cassette. These cells were able to grow on plates with kanamycin A at concentrations >1000 µg/ml, regardless of the presence of IPTG. The pools of binders were cloned into pQIA and plated under non-selective conditions (ampicillin, IPTG, no kanamycin A). About 1000 colonies from the N3C pool and 2000 colonies from the N2C pool were subsequently replica-plated under selective conditions (ampicillin, IPTG, kanamycin A (500 µg/ml)). By this procedure, 129 N3C and 69 N2C clones were identified which showed a kanamycinsensitive phenotype. The identified clones were ranked for their in vivo inhibition efficiency by spotting them on selective plates with different kanamycin A concentrations, ranging from 10 µg/ml to 500 µg/ml, and the most potent clones were sequenced. The sequencing revealed that variants of one potent inhibitor (AR_3 family) dominated the N3C inhibitor population, but also other sequences had been selected. Four different APH inhibitors (named AR_1, AR_2, AR_3a and AR_3b), with different in vivo performances, were chosen for further characterization (see Supplemental Data). While AR_1 was selected from the N2C library, AR_2, AR_3a and AR_3b came from the N3C library. AR_3a and AR_3b differ by three point mutations at the DNA level, causing two amino acid mutations. We also studied the properties of clone AR_B, a N2C molecule that binds APH but fails to inhibit the target enzyme. As a further control, the unselected AR protein E3_5 (21, 22) was tested in parallel. The characterization of these AR proteins included expression tests, determination of minimal inhibitory concentrations (MICs), ELISA, BIAcore and gel-filtration studies, as well as in vitro enzyme inhibition experiments.
In vivo performance (MIC)
The MICs of kanamycin A necessary to inhibit cell growth in liquid culture experiments were determined for the selected AR proteins. The plasmid pQIA with the non-binding control AR protein E3_5 as insert mediated resistance to kanamycin A (MIC > 1000 µg/ml) regardless of the presence of IPTG, showing that the expression of an AR protein per se has neither an influence on kanamycin A resistance nor on bacterial growth. Clone AR_B showed the same phenotype as E3_5 (Fig. 3B ). All AR proteins conferring kanamycin A sensitivity did not influence E. coli growth by themselves, even when induced, as long as no kanamycin A was present (Fig. 3B) . In contrast, induction of the inhibitors stopped growth at different kanamycin A concentrations ranging from 10 -150 µg/ml (Table I; Fig. 3B ). While clones AR_1 and AR_2 had MICs of 100 µg/ml and 150 µg/ml, respectively, clones AR_3a (25 µg/ml) and AR_3b (10 µg/ml) were more potent inhibitors (Table I) . To put these results into perspective, we also evaluated the natural resistance of E. coli to kanamycin A in the absence of APH. The MIC of E. coli carrying a pQIA variant, where the APH gene had been removed, expressing AR_B or AR_3a was found to be 5 µg/ml each. Taken together, these results lead to the conclusion that the most potent clones AR_3a and AR_3b showed a phenotype comparable to the APH gene knockout.
Expression of the selected AR proteins
As the selected AR proteins bind and inhibit APH inside the cell, we analyzed the expression of the selected clones in the selection vector pQIA under the expression conditions used for screening. Since the exact intracellular concentration of the AR proteins is difficult to determine, we performed a qualitative comparison of the selected clones by comparing the AR protein band intensities on Coomassiestained SDS-PAGE. All AR proteins were expressed as soluble proteins regardless of the vector and the expression conditions ( Figures 4A  and 4B ). The expression levels of clones AR_1, AR_3a and AR_3b seem to be similar and around two-fold higher than the one of clone AR_2. For in vitro studies we re-cloned the AR proteins into an expression vector (pQE30) to avoid co-purification of APH. All AR proteins could be purified to homogeneity in a single IMAC step by means of their His 6 -tag (Fig. 4C ). Around 100 mg purified AR protein could be obtained from a standard one-liter shake flask culture when expressed from the pQE30-derived vectors, without optimization of the expression and purification procedure. Even under selection conditions, where expression is not fully induced, the AR proteins show the most prominent bands on the gel (Fig. 4B) . As APH did not give rise to a pronounced band on the gel, the inhibitors must be present in large excess over APH in E. coli during screening.
Size exclusion chromatography of AR proteins and complexes
The selected AR proteins free or in complex with APH were analyzed by gel-filtration experiments. While most previously investigated AR proteins are monomers (13, 14) , different oligomerization tendencies, depending on the individual protein, were detected for the AR proteins described here (Fig. 5A) . AR_1 was monomeric, AR_B was present as monomer and trimer and AR_2, AR_3a and AR_3b appeared to be a mixture of monomer, dimer and soluble multimer (See Fig. 5A for data of AR_B, AR_1 and AR_3a). Reapplying single peaks from AR_3a resulted in a similar elution pattern, indicating equilibrium between the oligomeric states. The exact molecular weight of the different species was verified for AR_1 and AR_B by static light scattering (data not shown). Clone AR_1 (14.8 kDa) eluted at an apparent molecular weight of 15.2 kDa and clone AR_B (14.8 kDa) at 15.9 and 49.1 kDa. The molecular weight of the presumably monomeric and dimeric species of AR_3a and AR_3b could not be determined by static light scattering as the peaks strongly overlapped. Since AR_1 and most other selected and unselected library members are monomers (13, 14) , it seems likely that the oligomerization behavior is a consequence of the particularly selected interaction residues of the individual AR proteins. The complexes of the AR proteins with APH were also analyzed by gel-filtration experiments. All complexes gave one distinct symmetric peak, which was shifted to higher molecular weight, compared to the one of APH alone, and which corresponded to the correct molecular weight of the complex. For example, the complex of APH and AR_3a eluted in a single peak at an apparent molecular weight of about 47 kDa (calculated molecular weight: 49.6 kDa; Fig. 5B ), even though AR_3a alone eluted in various oligomeric states (Fig. 5A) . The complexes showed no signs of oligomeric states, supporting the hypothesis that the selected binding interfaces of the AR proteins are responsible for and may be directly involved in the observed partial oligomerization of some AR proteins (Fig. 5A) . Binding of the target thus abolishes oligomerization and leads to a defined 1:1 APH-AR protein complex. Indeed, co-purification of an APH mutant bound to AR_3a was used successfully for crystallization and structure determination of the complex as described elsewhere (24) . Binding constants and specificities of the inhibitors To investigate the binding properties of the selected AR proteins, the affinity and the specificity of the interaction were analyzed by ELISA and BIAcore studies. In an ELISA experiment with purified AR proteins of all analyzed clones, the binding to APH was compared to the binding to other proteins, such as pD, JNK2, p38, BSA and neutravidin (Fig. 6 ). p38 and JNK2 are two EPKs (32) sharing structural homology to APH. The selected AR proteins bind specifically to APH, but not to any of the other proteins (Fig. 6 ). As expected, the unselected AR protein E3_5 fails to bind any of the immobilized proteins. We conclude that specific APH-binding AR proteins were selected. To determine the dissociation constants of the selected AR proteins to APH, kinetic surface plasmon resonance (SPR) experiments were performed. The dissociation constants of all APH binders were found to be in the low to subnanomolar range (Table I ). K D s of the two highaffinity inhibitors AR_3a and AR_3b were verified by competition BIAcore (33); for details, see Supplemental Data). The SPR data were fitted with the assumption that all species (monomer, dimer, see above) share the same binding properties or convert to monomers upon binding. If this is not the case, the K D s given here reflect the average of all states.
In vitro inhibition of APH
To confirm that the in vivo effects of the selected AR proteins were indeed due to direct inhibition of the APH, in vitro enzyme assays were performed. Enzyme activity was monitored by coupling the release of ADP to a pyruvate kinase/lactate dehydrogenase reaction as described previously (McKay et al., 1994) with some modifications to adapt the assay for the inhibition studies (see Experimental Procedures). The inhibition assay was set up to mimic the in vivo situation, where the AR protein concentration is higher than the one of APH and the kanamycin A concentration is low, since it has been suggested that kanamycin A import is the rate-limiting process (34) . For all clones showing a kanamycin A sensitive phenotype in vivo, enzyme inhibition was detected, while the control proteins E3_5 and AR_B showed no significant influence on APH activity (Fig. 7) . Under these conditions, the inhibition was not complete (200 nM APH, 10 µM AR protein); a remaining activity, ranging from 6 -52%, depending on the individual inhibitor, was found (Fig. 7A) . The kinetic experiments with kanamycin A were complicated by an apparent substrate inhibition of at low micromolar concentrations (Fig. 7C) . Substrate inhibition had previously been described at higher kanamycin A concentrations (28) . The measurement were thus repeated with amikacin, another aminoglycoside substrate of APH containing an additional hydroxybutyrate group, which does not show substrate inhibition and has a similar turnover rate (McKay et al., 1994, Fig.   7C, D) . Again, APH activity was reduced to 2 -73%, depending on the respective AR inhibitor, while control proteins E3_5 and AR_B did not show significant influence on activity (Fig. 7B) . Thus, the overall in vitro inhibition of APH by the AR proteins using amikacin as substrate was similar to that observed when using kanamycin A (Fig. 7A) . A more detailed characterization of AR_3a is given elsewhere, including precise titration analysis and structural insights in the inhibition mechanism (24) . The different inhibition efficiencies of the selected inhibitors seem to correlate well with the differences in K D s and their inhibition performance in vivo (Table I) . Nevertheless, it is worth commenting on the fact that residual activities were found at a concentration of AR proteins that is 10 3 -10 4 -fold above the K D values determined by BIAcore analysis. Some of the APH/AR protein complexes may indeed possess a residual activity. However, there are other possible factors leading to this observation: (i) the presence of the substrates, ATP and aminoglycoside, acting as competitor for a distinct conformation of APH, which will raise K I correspondingly above the K D values; (ii) increased K D values of the complexes as a result of different assay conditions of the kinetic measurements (e.g. increased temperature and different buffer composition); (iii) overestimation of the concentration of active AR proteins due to some degree of oligomerization (Fig. 5 ). One more difference should be noted: the inhibition of APH by AR_1 was less efficient with amikacin as a substrate (73% residual APH activity) than with kanamycin A (43% residual APH activity) under the assay conditions (Fig.  7A, B) . In vivo tests revealed that AR_1, in contrast to the other inhibitors, did not increase the amikacin sensitivity of E. coli harboring the appropriate plasmid, but displayed the same phenotype as the non-inhibitors E3_5 and AR_B (data not shown). These results suggest that amikacin can compete more efficiently than kanamycin A with the binding of AR_1 to APH. In summary, all AR proteins tested showed direct inhibition of APH, even though the inhibition was not complete except for the case of AR_3b and AR_3a, and might be substratespecific in case of AR_1.
Discussion
Methods that are able to directly and specifically interfere with the function of a protein of interest intracellularly are necessary to validate results obtained from gene knockouts and especially from RNAi and antisense approaches. In addition, they give further insights into the protein itself. The difficulty to create specific and intracellularly active binders and inhibitors to most proteins has, however, so far constituted a bottleneck in elucidating the function of many proteins. By the rapid generation of selective high-affinity intracellular enzyme inhibitors we demonstrate here that designed AR proteins have the potential to solve this problem. The most potent inhibitors lead to a phenotype that is comparable to a gene knockout. This potency is achieved by a combination of factors: The selected AR proteins are free of disulfide bonds, they are able to fold well and are stable in the reducing intracellular environment, they are expressed in soluble form at high levels in the cytoplasm and the interaction with the target enzyme is of high affinity and specificity. The combination of these factors leads to a clear advantage of AR proteins as intracellular inhibitors over antibodies, peptides or other binding proteins reported so far.
Intracellular protein inhibitors
The approach to obtain intracellular protein inhibitors presented here, based on designed AR proteins, is very promising. While high affinities are rather difficult to achieve with peptidic binders (except in the case of target proteins with pronounced binding pockets), the affinity and specificity of antibodies and designed AR proteins are good and comparable. The main drawback of antibodies for intracellular applications is that their stabilities rely on disulfide bonds, which cannot form in the reducing intracellular environment. Consequently, low levels of soluble functional protein and limited half-life of the antibody domains, due to aggregation, are the rule when applied in the cytoplasm (Biocca et al., 1995) . In this respect, the high intracellular expression level and stability of designed AR proteins is a clear advantage. It seems highly probable that these properties were responsible that we could identify not only a few individual, but a number of different functional inhibitors, even though the selection system described here selects for intracellular stability and enzyme inhibition at the same time. Several approaches have been described to generate antibodies that are active intracellularly (for details see reviews: (8, 35) . While the inhibition of enzymes in vitro by antibodies has often been described (36) (37) (38) , only few of these inhibitors have been applied intracellularly (39) . Besides antibodies and AR proteins, other protein scaffolds have been used for the generation of enzyme inhibitors. Different highaffinity protease inhibitors have been generated based on protease-inhibitor scaffolds (Stoop and Craik, 2003) , and the function of β-lactamase inhibitory protein BLIP has been improved (40) . These scaffolds mostly exploited naturally occurring enzyme inhibitors that were improved for affinity or specificity. All these inhibitors contain disulfide bonds and were used for extracellular or periplasmatic applications.
In vivo inhibition of APH
The choice of APH as a model system was guided by several aspects of the enzyme. APH phosphorylates aminoglycoside antibiotics (e.g. streptomycin, kanamycin or amikacin), mediating bacterial resistance to these antibiotics. This allowed the set-up of an efficient screening assay for the identification of inhibiting AR proteins (Fig. 3) . Most importantly, APH displays high structural homology to EPKs (23), a class of enzymes involved in a wide range of diseases (see below). Finally, no satisfactory APH inhibitors are known to date that are active in vivo. While different in vitro inhibitors of APH have been described in the literature (41, 42) , they fail to inhibit bacterial growth efficiently. We describe here the first inhibitors that are fully functional in vivo and show a phenotype comparable to the APH gene knockout. Although the selected AR proteins are per se not suitable as antibiotic agents on their own, they could in the future accelerate the process of drug discovery by providing a detailed structure of the drug target in an inactive state. This aspect is discussed elsewhere (24) , where the crystal structure of the selected AR protein AR_3a in complex with an APH mutant was determined.
Targeting eukaryotic protein kinases
EPKs receive widespread interest, as they are key players in cellular signaling, making them targets for the treatment of a number of diseases, such as various cancers, asthma, and autoimmunity to name a few (43) . In the case of EPKs, highly selective inhibitors are desired (for a recent review on the EPK inhibitor field see (44) . However, the generation of specific EPK inhibitors is difficult, due to the large number of EPKs (around 518 in human; (43) ), all sharing highly homologous active sites and using ATP as a co-factor. Most inhibition strategies involve targeting of the ATP-binding pocket by small molecular weight drugs. This is not ideal, as this region of EPKs is highly conserved and thus specificity is difficult to achieve, and is further complicated by the high ATP level inside the cell (1 mM) that must be competed. Indeed, APH is inhibited by some EPK inhibitors, which on the one hand underlines the structural homology of APH and EPKs and on the other hand also demonstrates the poor specificity of these EPK inhibitors (45) . Proteinaceous inhibitors could represent an attractive alternative, since they can interact via a large surface and, therefore, their binding is not restricted to grooves. This enables them to bind to the less conserved surface regions on the target protein while blocking its function. It is noteworthy that many natural AR proteins are kinase inhibitors, such as for example the cell division kinase inhibitors p16
INK4a and p19
INK4d (46, 47) . We have already successfully demonstrated the selection of MAP kinase binders from designed AR protein libraries (13) . Again, the selected pools of binders might serve as starting point for inhibitor screens, in this case using an in vitro activity assay. Since MAP kinases are part of signaling networks, functional inhibition might not only be achieved by inhibition of the catalytic site, but also by simple binding, provided the inhibitor blocks either the protein substrate or the activation of the kinase itself by an upstream kinase. While our approach can be applied now as a discovery tool, therapeutic intracellular applications of designed AR proteins will have to await further maturation of gene therapy or protein-uptake techniques. (14) and (21).
Fig. 2.
Enrichment and specificity of ribosome-display selection rounds. The outcome of ribosomedisplay selection rounds was monitored at the level of RT-PCR product yield by agarose gel electrophoresis. The RT-PCR yield of the first and the second selection round were compared for both the N2C-and N3C-library. In the third round the specificities of the selected pools of the N2C-and the N3C-library were checked by panning against APH and an unrelated protein, MBP. All experiments were done in duplicates, which were combined for the agarose gel. For the specificity check of panning on the control protein MBP, both N2C and N3C duplicates were combined. and in the presence of 2 µM AR proteins, the corresponding APH activity is reduced to 2 -73%. Again, the control proteins E3_5 and AR_B show no significant influence on APH activity. For AR_3b, the inhibition is essentially complete. (C, D) APH kinetics were measured at 37°C using 50 nM of purified monomeric APH as described in the Materials and methodssection and two different substrates, kanamycin A (C) and amikacin (D). Initial velocities are plotted against substrate concentrations. (C) When using kanamycin A as a substrate, a pronounced apparent partial substrate inhibition in the low micromolar range was observed. At high kanamycin A concentrations, k obs is reaching 1.64 s -1 . Even though substrate inhibition of kanamycin A was previously reported (McKay and Wright, 1995), it seemed to be observed at lower substrate concentrations under our experimental conditions. (D) The activity of APH followed Michaelis-Menten kinetics when using the substrate amikacin. The initial rates were fitted by nonlinear least squares fitting using the standard MichaelisMenten equation. The determined K m and k cat values were 418 ± 29 µM and 6.56 ± 0.17 s -1 , respectively. (29) . A standard round consisted of a 30-minute pre-panning step on neutravidin, another pre-panning step of 30 minutes on avi-pD-His 6 , to avoid selecting binders against BSA, neutravidin or pD, followed by a 60-minute panning step on avi-pD-His 6 -APH (bound to neutravidin, blocked with BSA). Following selection, RNA purification and RT (with oligonucleotide tolAk), a first PCR was made using oligonucleotides T7B (5'-ATACGAAATTAATACGACTCACTATAGGGAGACCACAACGG-3') and tolAk (5'-CCGCACACCAGTAAGGTGTGCGGTTTCAGTTGCCGCTTTCTTTCT-3'). This RT-PCR product was agarose-gel purified and reamplified in a second PCR using the same oligonucleotides. This second PCR product served as template for the next round of ribosome display. The number of total RT-PCR cycles was reduced from round to round from 40 to 35 to 30, adjusting to the yield due to enrichment of binders.
Construction of selection vector for replica screening -For the in vivo selection, the vector pQIA was constructed with β-lactamase and APH dicistronically arranged under the control of the β-lactamase promoter, as well as an expression cassette for AR proteins under the control of an IPTG-inducible T5-promoter (Fig. 3A) . For this purpose, the APH gene was PCR amplified from pETSACG1 with the oligonucleotides APHsspf (5'-TTTCAATATTTTAAAACAATTCATCCAGTAAAATATAGTATTTTATTTTC-3') and APHsspr (5'-TTCAATAATATTGAAAAAGGAAGAGTATGGCTAAAATGAGAATAT-3').
The PCR product was purified, cut with SspI and ligated into pQI_pD (pAT194, GenBank accession number AY327142), a pQE30 derivative with additional lacI q gene and pD under the control of the T5 promoter, cut with the same enzyme, to yield pQIA_pD, where the APH open reading frame lies directly downstream of the one of β-lactamase in dicistronic manner. The proper function of the APH gene was confirmed by successful growth of XL1-Blue cells harboring pQIA_pD in the presence of 50 µg/ml kanamycin A. For later cloning of the APH-binding AR protein pool, the multiple cloning site and pD of pQIA_pD was replaced with the one of pPANK (GenBank accession number AY327140) containing the unselected AR protein E3_5 (GenBank accession number AY195853), yielding the in vivo selection plasmid pQIA containing the naïve AR protein E3_5 gene as a dummy insert under the control of the IPTG-inducible T5 promoter (Fig. 3A) . The pools of binders selected by ribosome display were cloned into pQIA using the restriction enzymes BamHI and HindIII, replacing the E3_5 gene, transformed into E. coli (XL1-Blue) and plated on LB agar plates, containing 1% glucose, 50 µg/ml ampicillin and 100 µM IPTG, and incubated overnight at 37°C.
Protein production and purification -Non-biotinylated wild-type APH used for the in vitro kinetic assays was expressed from pETSACG1 in BL21 cells (Stratagene) and purified over a Q-Sepharose column (Amersham Pharmacia, Dübendorf, Switzerland), followed by gel-filtration (Superdex 75; Pharmacia) as described (28) with some modifications. After expression, the cell pellet of one liter bacterial culture was resuspended in 25 ml TBS 500 (50 mM Tris-HCl pH 8.0, 500 mM NaCl). The cells were lysed using an Emulsiflex C5 (Avestin, Ottawa, ON, Canada). The cell debris was pelleted by centrifugation at 30'000 g for 30 minutes at 4°C. The resulting supernatant was applied to a 25 ml Q-Sepharose column (Amersham Pharmacia, Dübendorf, Switzerland) equilibrated with buffer 1 (50 mM Tris-HCl pH 8.0). APH was eluted by a linear gradient with increasing buffer 2 (50 mM Tris-HCl pH 8.0, 1 M NaCl). Fractions containing APH were identified by SDS-PAGE analysis, pooled, and 10 mM MgCl 2 and 2 mM dithiothreitol (DTT) were added. APH was further purified by a preparative Superdex-75 (Amersham Pharmacia, Dübendorf, Switzerland) size exclusion chromatography step in 50 mM HEPES pH 7.5, 200 mM NaCl, 10 mM MgCl 2 and 2 mM DTT, according to the published protocol (Hon et al., 1997) . The peak fraction with an approximate molecular weight of the monomeric APH was collected and used for further experiments. The correct size of APH was confirmed by SDS-PAGE, mass spectrometry and static light scattering.
Supplemental Figures
Supplemental Figure S1 -Sequences of the selected AR proteins. The N-terminal capping repeat is coloured in blue, the two or three randomized repeats are in black and the C-terminal capping repeat is in red. E3_5 is an unselected AR protein; AR_1, AR_2, AR_3a and AR_3b are APH inhibitors, while AR_B binds APH without inhibiting it. Note that AR_1 and AR_B are N2C molecules, while E3_5, AR_2, AR_3a and AR_3b are N3C molecules. For comparison, the N3C library input sequence is given on the top of the sequence alignment. In the alignment, only differences compared to the input sequence are highlighted. x represents any amino acid except cysteine, glycine or proline; z represents any of the amino acids asparagine, histidine or tyrosine.
